Coldchain Technology Services, a Leading Vaccine Supply Chain Management Company to the US Government Selects Draganfly to Provide Vaccine Payload System and Flight Services for COVID-19 Vaccine
Los Angeles, CA., Dec. 22, 2020 (GLOBE NEWSWIRE) — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer, is pleased to announce that the Company has been selected by Coldchain Technology Services, LLC (“Coldchain Technology”) to immediately develop and provide flight services of a robust vaccine delivery payload for use in critical regions for drone delivery of the COVID-19 vaccine.
Coldchain Technology provides comprehensive solutions for healthcare supply chain management for multiple government and commercial clients, including the US Army, the Centers for Disease Control and Prevention, Reserve Component forces, Johnson & Johnson brands, Chicago Department of Public Health, and others and has been leading the deployment of COVID-19 vaccines throughout the United States.
The payload to be developed by Draganfly is a sustainable thermal management system with capability to carry a minimum of 300 multi-doses or 100 single doses. It is being designed as part of a comprehensive delivery and logistics platform of which Draganfly will operate.
“It is very exciting that COVID-19 vaccinations are starting to be distributed. Draganfly will help us solve the problem which is the timely and precise distribution of the vaccine in hard-to-reach areas.” said Wayne Williams, Founder and Executive Director of Coldchain Technology.
“Since the beginning of the COVID-19 pandemic, Draganfly has been committed to providing solutions to help prevent the spread of the virus, including our Vital Intelligence systems that can measure vital signs from a camera including your smartphone.” said Cameron Chell, CEO of Draganfly. “We are eager to develop this payload and service as we can leverage our extensive patent portfolio as well as secure auto-pilot and flight management system to help with the distribution of the vaccine for Covid-19 and beyond.”
About Coldchain Technology
Coldchain Technology is the leader in time and temperature sensitive medical material management integrating proven systems with the documentation fundamental to accreditation and effective Quality Control Systems. Coldchain Technology’s remote monitoring system, pre-qualified thermal shippers, inventory control, fulfillment, and QAQC solutions ensure the Integrity and Security of its client’s product. www.coldchain-tech.com.
About Draganfly
Draganfly Inc. (CSE: DFLY; OTCQB: DFLYF; FSE: 3U8) is the creator of quality, cutting-edge and software and systems that revolutionize the way organizations can do business and service their stakeholders. Recognized as being at the forefront of technology for over 22 years, Draganfly is an award-winning, industry-leading manufacturer and technology developer serving the public safety, agriculture, industrial inspections, security, and mapping and surveying markets. Draganfly is a company driven by passion, ingenuity, and the need to provide efficient solutions and first-class services to its customers around the world with the goal of saving time, money, and lives.
For more information on Draganfly, please visit us at www.draganfly.com.
For additional investor information, visit https://www.thecse.com/en/listings/technology/draganfly-inc, https://www.otcmarkets.com/stock/DFLYF/overview or https://www.boerse-frankfurt.de/aktie/draganfly-inc.
Media Contact
Arian Hopkins
email: [email protected]
Company Contact
Email: [email protected]
Forward-Looking Statements
This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements include, but are not limited to, statements with respect to the successful development of the vaccine drone delivery payload system. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company’s business, operations and financial condition, the successful integration of technology, the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties disclosed under the heading “Risk Factors“ in the Company’s most recent filings filed with securities regulators in Canada on the SEDAR website at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements’ best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
Recent Comments